Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ibrutinib + RICE
- Development stage
- Unknown
- Lead developer
- Pharmacyclics
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ibrutinib + RICE is a combination therapy used in the treatment of relapsed or refractory mature B-cell non-Hodgkin lymphoma (B-NHL), particularly in pediatric and young adult patients. Ibrutinib is a small molecule inhibitor that irreversibly binds to Bruton's tyrosine kinase (BTK), blocking B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival. The RICE regimen consists of rituximab (a monoclonal antibody targeting CD20 on B cells), ifosfamide (an alkylating agent), carboplatin (a platinum-based chemotherapeutic), and etoposide (a topoisomerase II inhibitor). This combination aims to enhance anti-tumor activity by integrating targeted BTK inhibition with established cytotoxic chemotherapy. Ibrutinib was developed by Pharmacyclics and is marketed as Imbruvica[1][4][5][6].
- Other names
- rituximabifosfamidecarboplatinetoposide
02
Targets
Beyond the preview
Go deeper on Ibrutinib + RICE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ibrutinib + RICE.